Between 10% and 15% of Americans who take a daily aspirin to prevent cardiovascular events are resistant to the drug and may not substantially benefit from the regime, according to a Duke University study reported in the Journal of the American College of Cardiology. Researchers devised an RNA blood test to identify how effective aspirin treatment was likely to be. It's not clear whether higher doses of aspirin would help, researcher Dr. Geoffrey S. Ginsburg said, calling the study "another step in more personalized medicine."
RNA signature points to whether patients will respond to aspirin, study finds
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||